Premium
Growth Rates and Responses to Treatment in Human Myelomatosis
Author(s) -
Hobbs J. R.
Publication year - 1969
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1969.tb00441.x
Subject(s) - bence jones protein , multiple myeloma , doubling time , medicine , gastroenterology , immunology , cell , biology , immunoglobulin light chain , antibody , genetics
Summary: Studies of myelomatosis during the M.R.C. trial have shown that the average doubling times for paraprotein levels were 10.1 months for γG, 6.3 months for γA and 3.4 months for Bence‐Jones myelomata. These findings suggest that from a single mutant cell it takes on average 33, 21 and 11 years respectively for the clinical emergence of these three types of myeloma. Four biochemical types of response to treatment were found and a slow response carried the best prognosis. ‘Bence‐Jones escape’, observed in 15 patients, indicates the need to monitor the urine during treatment.